We are live on ! Find out more
OPTR

OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR

Delisted

OPTR was delisted on the 23rd of October, 2013.

Back to rankings

103 hedge funds and large institutions have $642M invested in OPTIMER PHARMACEUTICALS, INC. COM STK in 2013 Q2 according to their latest regulatory filings, with 103 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $20.5M | Put options by funds: $16.4M

Holders
103
Holders Change
+103
Holders Change %
–
% of All Funds
3.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
103
Increased
–
Reduced
–
Closed
–
Calls
$20.5M
Puts
$16.4M
Net Calls
+$4.08M
Net Calls Change
+$4.08M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$74.2M +$74.7M +5,127,008 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$68.7M +$69.1M +4,745,961 New
Wellington Management Group
3
Wellington Management Group
Massachusetts
$50.1M +$50.5M +3,465,016 New
DM
4
Deerfield Management
New York
$43.8M +$44.1M +3,025,829 New
GIM
5
Granahan Investment Management
Massachusetts
$38.1M +$38.4M +2,636,421 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$37.6M +$37.8M +2,595,570 New
BFA
7
BlackRock Fund Advisors
California
$26.6M +$26.8M +1,839,255 New
State Street
8
State Street
Massachusetts
$24.4M +$24.6M +1,686,170 New
QF
9
QVT Financial
New York
$23.6M +$23.7M +1,629,800 New
PCM
10
Pentwater Capital Management
Florida
$22.4M +$22.6M +1,550,000 New
BB
11
BB Biotech
Switzerland
$20.9M +$21.1M +1,446,700 New
Citadel Advisors
12
Citadel Advisors
Florida
$20.3M +$20.4M +1,400,334 New
BIT
13
BlackRock Institutional Trust
California
$19.9M +$20M +1,371,911 New
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$10.3M +$10.4M +714,087 New
Northern Trust
15
Northern Trust
Illinois
$10.2M +$10.3M +704,540 New
UBS AM
16
UBS AM
Illinois
$9.56M +$9.62M +660,955 New
AllianceBernstein
17
AllianceBernstein
Tennessee
$8.87M +$8.93M +613,050 New
O
18
OrbiMed
New York
$7.76M +$7.81M +536,000 New
AIM
19
Allen Investment Management
New York
$7.24M +$7.28M +500,000 New
MG
20
Meditor Group
Bermuda
$6.87M +$6.92M +475,000 New
Axa
21
Axa
France
$6.72M +$6.76M +464,317 New
VOYA Investment Management
22
VOYA Investment Management
Georgia
$5.09M +$5.12M +351,746 New
SGA
23
Sector Gamma AS
Norway
$4.94M +$4.97M +341,393 New
Deutsche Bank
24
Deutsche Bank
Germany
$4.94M +$4.97M +341,463 New
JP Morgan Chase
25
JP Morgan Chase
New York
$4.69M +$4.72M +324,359 New
1
2 3 4 5

OPTR Hedge Fund Activity: Q2 2013 in Review

103 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) for Q2 2013, worth a combined $642M.

Buyers outnumbered sellers: 103 funds opened new OPTR positions and 0 closed out — a net gain of 103 holders — while 0 added to existing stakes and 0 trimmed.

  • 103 institutional investors held OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $642M of OPTIMER PHARMACEUTICALS, INC. COM STK stock for Q2 2013.
  • 103 funds opened new OPTIMER PHARMACEUTICALS, INC. COM STK positions in Q2 2013 and 0 closed out, a net change of +103 holders.

Based on aggregated 13F filings for Q2 2013.